Literature DB >> 32666056

Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.

Sakda Sathirareuangchai1, David Shimizu1,2, Koah Robin Vierkoetter1,2.   

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is a rare lung disease characterized by diffuse cystic changes caused by a destructive proliferation of smooth muscle-like cells or LAM cells. It is a part of the perivascular epithelioid cell family of tumors. LAM may be associated with the genetic disorder tuberous sclerosis complex or may occur sporadically. Individuals affected by LAM are typically females of child-bearing age who present with recurrent spontaneous pneumothorax. The microscopic findings can be subtle and careful examination is needed to identify the neoplastic cells of LAM. Immunohistochemical markers in cases of LAM demonstrate a characteristic co-expression of myogenic and melanocytic markers. We report a case of a 41-year-old woman who presented with multiple episodes of spontaneous pneumothorax and microscopic findings characteristic of LAM. ©Copyright 2020 by University Health Partners of Hawai‘i (UHP Hawai‘i).

Entities:  

Keywords:  Pulmonary lymphangioleiomyomatosis; spontaneous pneumothorax; tuberous sclerosis

Mesh:

Year:  2020        PMID: 32666056      PMCID: PMC7350511     

Source DB:  PubMed          Journal:  Hawaii J Health Soc Welf        ISSN: 2641-5216


  23 in total

Review 1.  The changing face of Pneumocystis carinii pneumonia in AIDS patients.

Authors:  P M Boiselle; C A Crans; M A Kaplan
Journal:  AJR Am J Roentgenol       Date:  1999-05       Impact factor: 3.959

Review 2.  Diffuse Cystic Lung Disease. Part II.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

3.  Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm.

Authors:  Francis X McCormack; William D Travis; Thomas V Colby; Elizabeth P Henske; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2012-12-15       Impact factor: 21.405

4.  Pulmonary lymphangioleiomyomatosis.

Authors:  Xuchen Zhang; William D Travis
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

5.  Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.

Authors:  K Matsui; M B Beasley; W K Nelson; P M Barnes; J Bechtle; R Falk; V J Ferrans; J Moss; W D Travis
Journal:  Am J Surg Pathol       Date:  2001-04       Impact factor: 6.394

6.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Authors:  Francis X McCormack; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Charlie Strange; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Lisa R Young; Brent W Kinder; Gregory P Downey; Eugene J Sullivan; Thomas V Colby; Roy T McKay; Marsha M Cohen; Leslie Korbee; Angelo M Taveira-DaSilva; Hye-Seung Lee; Jeffrey P Krischer; Bruce C Trapnell
Journal:  N Engl J Med       Date:  2011-03-16       Impact factor: 91.245

7.  β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis.

Authors:  Richard J Flavin; Jennifer Cook; Michelangelo Fiorentino; Dyane Bailey; Myles Brown; Massimo F Loda
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

8.  Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis.

Authors:  F Bonetti; P L Chiodera; M Pea; G Martignoni; F Bosi; G Zamboni; G M Mariuzzi
Journal:  Am J Surg Pathol       Date:  1993-11       Impact factor: 6.394

9.  Lung transplantation for lymphangioleiomyomatosis: the French experience.

Authors:  Martine Reynaud-Gaubert; Jean-François Mornex; Hervé Mal; Michèle Treilhaud; Claire Dromer; Sébastien Quétant; François Leroy-Ladurie; Romain Guillemain; François Philit; Gaëlle Dauriat; Dominique Grenet; Marc Stern
Journal:  Transplantation       Date:  2008-08-27       Impact factor: 4.939

Review 10.  Lymphangioleiomyomatosis.

Authors:  Simon R Johnson; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Clin Chest Med       Date:  2016-09       Impact factor: 2.878

View more
  2 in total

1.  Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections.

Authors:  Wenying Lu; Mathew Suji Eapen; Gurpreet Kaur Singhera; James Markos; Greg Haug; Collin Chia; Josie Larby; Samuel James Brake; Glen P Westall; Jade Jaffar; Rama Satyanarayana Raju Kalidhindi; Nimesha De Fonseka; Venkatachalem Sathish; Tillie L Hackett; Sukhwinder Singh Sohal
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

2.  Pulmonary lymphangioleiomyomatosis (LAM): A literature overview and case report.

Authors:  Cung-Van Cong; Tran-Thi Tuan Anh; Tran-Thi Ly; Nguyen Minh Duc
Journal:  Radiol Case Rep       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.